A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan

Respiratory Investigation

Volumn 53, Issue 2, 2015, Pages 51-59

  Bando, Masashi ^a   Sugiyama, Yukihiko ^a   Azuma, Arata ^b   Ebina, Masahito ^c   Taniguchi, Hiroyuki ^d   Taguchi, Yoshio ^e   Takahashi, Hiroki ^f   Homma, Sakae ^g   Nukiwa, Toshihiro ^h   Kudoh, Shoji ⁱ  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c Tohoku Medical and Pharmaceutical University Hospital   (Japan)

^d TOSEI GENERAL HOSPITAL   (Japan)

^e TENRI HOSPITAL   (Japan)

^f SAPPORO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^g TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^h South Miyagi Medical Center   (Japan)

ⁱ Respiratory Medicine   (Japan)

Author keywords

Idiopathic interstitial pneumonias; Idiopathic pulmonary fibrosis; Prospective multicenter epidemiological study; Web registration

Indexed keywords

ACETYLCYSTEINE; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; KREBS VON DEN LUNGEN 6; PIRFENIDONE; RHEUMATOID FACTOR; STEROID; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; PYRIDONE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRACKLE; DIABETES MELLITUS; DIGITAL CLUBBING; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG USE; DYSPNEA; DYSPNEA ON EXERTION; FAMILY HISTORY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LUNG BIOPSY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROSPECTIVE STUDY; REGISTER; RESPIRATORY FAILURE; SEX RATIO; SMOKING; SURVIVAL; THORAX RADIOGRAPHY; IDIOPATHIC INTERSTITIAL PNEUMONIAS; INTERNET; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PROGNOSIS; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME FACTOR;

AGED; FEMALE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; INTERNET; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDONES; REGISTRIES; SURVIVAL RATE; TIME FACTORS;

EID: 84924814651     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2014.11.001     Document Type: Article

References (18)

1. Japanese Respiratory Society's Committee Formulating Diagnosis and Treatment Guideline for Diffuse Lung Diseases. Revised 2nd edition guidelines for diagnosis and treatment of idiopathic interstitial pneumonias, Nankodo, Tokyo, 2011.
2. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
3. Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:431-440.
4. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:821-829.
5. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiological survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014, 190:773-779.
6. Ohno S, Nakaya T, Bando M, et al. Idiopathic pulmonary fibrosis-results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008, 13:926-928.
7. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000, 161:646-664. American Thoracic Society.
8. Taguchi Y, Inoue T. Main symptoms and physical findings in clinical diagnostic criteria. Health, labour and welfare grant-in-aid for scientific research, diffuse lung diseases research FY 2000 research report. 2001. p. 96-99.
9. Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung disease. Respir Invest 2012, 50:3-13.
10. Ohnishi H, Yokoyama A, Kondo K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Cirt Care Med 2002, 165:378-381.
11. Miyazaki A, Azuma N, Inase T, et al. A randomized, double-blind, multi-centered controlled trial of cyclosporine a vs. cyclophosphamide with corticosteroid in patients with idiopathic pulmonary fibrosis in Japan. In: Proceedings of the 2011 American Thoracic Society international conference. Denver, CO, USA. Chapter, ; publication date 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A381210.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A3812.
12. King TE, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001, 164:1171-1181.
13. Martinez JF, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005, 142:963-967.
14. Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis. Chest 2010, 137:129-137.
15. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011, 140:221-229.
16. Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012, 40:1001-1109.
17. Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis. A cohort study. Am J Respir Crit Care Med 2011, 184:842-847.
18. Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010, 27:103-110.